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Materials
• To adapt a novel, physiologically relevant,
three-­dimensional skeletal muscle model and
confirm that it is usable in future studies
• To fabricate myobundles which contract
spontaneously in response to electrical and
chemical stimulation
• To develop a tool for pharmacological testing
and disease modeling
• To provide an alternative to costly animal
studies, mitigating ethical considerations and
reducing the number of in vivo and ex vivo
models
• Existing in vitro models for liver, lung, and
cardiac tissue have made recent notable
progress, however a predictive model of
human skeletal muscle does not exist
• There are many metabolic, neuromuscular,
and dystrophic disorders of the skeletal
muscle that currently lack therapies
• Disease of the skeletal muscle has high
societal impact including diabetes, obesity,
and various dystrophies
• Skeletal muscle involved in interactions
between organs has been important in
cognition, aging, inflammation, and cancer
• Two-­dimensional cultures of myoblasts are
well known but these cultures lack the
organization and function of a native muscle
and are hard to maintain over time
• The usefulness of these existing models in
pharmacological studies and disease
modeling is limited
Figure 3. Laser-­cut Cerex
teflon frames fit into the
outer ridge of the PDMS
molds.
• Proceed to vary the cell type and
concentration in order to find cells for optimal
growth in the three-­dimensional matrix
• Use micro patterned PDMS silicon to orient
myotubes for growth and differentiation
• Histological staining to confirm mature
myobundles
• Measure the contractile and biochemical
responses of myobundles to determine their
usability in preclinical testing and disease
modeling
• Use human iPSCs to allow for production of
human muscle cells and also allow generation
of patient specific cells that can harbor
mutations leading to disease states, such as
muscular dystrophy
• Study the effects of the TRIM protein MG53
on membrane resealing
Purpose
Figure 1. Negative molds were used to generate
multiple replicas of the positive PDMS molds. Three
prototypes of negative molds are pictured above. From
left to right: (left) 3D printed polylactic acid (PLA)
plastic, (middle) initial laser cut acrylic plastic with
incorrect dimensions, (right) current model of laser cut
acrylic plastic with the correct dimensions.
• Attachment to the frame has been observed
but cell death has soon followed
• Our observations do prove, however, that
formation of the myobundle is possible with
this model and that with continued alteration
the myobundle should survive for use in
further testing
Figure 4. C2C12 cells, mouse myoblast cell line (left),
were cultured in Dulbecco's Modified Eagle's Medium
with 10% fetal bovine serum and then differentiated to
form multinucleated myotubes (right).
Figure 6. Expanded myoblasts were dissociated in
TrypLE, pelleted, and resuspended to give a working
concentration of 15×106 cells/mL.
Figure 7. The graphic on the left is a representation of
cells and matrix viewed from above. The graphic on the
right is a side view of matrix and cells seeded in the
positive mold. The grey line is representative of the
frame which is in contact with the cell suspension.
7.5×105cells
+17  μL  media
33  μL  matrix  
(Matrigel  or  methyl  
cellulose)
Prepare  on  ice
Mix  just  before  
pipetting  onto  
mold
50  μL  total  per  
well
Figure 2. Positive molds
were cast from negative
molds using Sylgard 184
Elastomer cured for 24
hours at 64°C.
Figure 5. H9C2 cells, a subclonal line derived from
embryonic rat heart tissue. Myoblasts (left) were
cultured in Dulbecco's Modified Eagle's Medium with
10% fetal bovine serum and then differentiated to form
multinucleated myotubes (right).
37°C  incubation,
30  min  for  gelling
37°C  incubation,
3-­5  days  for  compaction
mold  +  frame  +  gelled  myobundle
covered  with  growth  media
frame  removed  from  mold,  
placed  in  differentiation  media
37°C  incubation,
1-­4  weeks  with  observations
Figure 8. Myobundle fabrication procedure following
initial plating of mold. Images (Madden et al.).
